Spark Biomedical's CEO, Daniel Powell, to Speak at Congressman Dan Crenshaw 3rd Annual Healthcare Innovation Summit
July 22, 2021 — Spark Biomedical, Inc. is honored to speak at Congressman Dan Crenshaw's (R-TX) Third Annual Healthcare Innovation Summit on Friday, July 23, 9:00 a.m. – 11:30 a.m. CT at Rice University. Spark CEO, Daniel Powell, will be among five healthcare leaders scheduled to speak during the Summit.
This Summit is designed to bring together some of the most brilliant and forward-thinking healthcare leaders in Texas and across the country to discuss cutting-edge research, breakthroughs in medical technology, and the latest in healthcare innovation.
Daniel Powell commented, "Spark is honored to be among this prestigious gathering of healthcare innovators. We're looking forward to sharing more about our FDA-cleared technology for opioid withdrawal relief, what we're planning in the near future, and also hope to shed some light on the urgent need for pioneering changes to address the opioid epidemic."
Want To Attend?
The live event will be streamed via Zoom from 9:00 a.m. – 11:30 a.m. CT, Friday, July 23rd. Anyone wishing to attend virtually may do so using the link below.
The full lineup at this year's Summit include:
During the Summit, Crenshaw will award the Susan Crenshaw Congressional Healthcare Innovation Award, named for Crenshaw's late mother. The award recognizes selfless members of the Texas community who have dedicated their lives to propelling healthcare innovation forward. Susan Crenshaw lost her battle with cancer after serving as patient #1 for an innovative cancer treatment that is now one of the most effective treatments available.
About Spark Biomedical, Inc.
Spark Biomedical, Inc. is a Texas-based medical device company and developer of the first drug-free, personalized, wearable solution for opioid withdrawal relief backed by evidence from a double-blind, randomized controlled clinical trial targeting patients with opioid use disorder.
The Sparrow Therapy System uses Transcutaneous Auricular Neurostimulation (tAN) to treat withdrawal symptoms by stimulating nerves on and around the ear. The wearable earpiece is designed to be worn up to 24 hours a day throughout opioid reduction or as prescribed to aid in the reduction of withdrawal symptoms.
The company's vision to ignite a brighter future for those struggling with opioid use disorder and dependence is fueled by its unique blend of scientific expertise, technical innovation, and deep medical device industry experience.